Ackman: Valeant's main problem is PR, not fraud
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages
October 30, 2015 12:57 PM EDTThe bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.
This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More
Valeant Pharma (VRX) falls below $100 again
October 30, 2015 11:58 AM EDTValeant Pharma (NYSE: VRX) falls below $100 again
... MoreBill Ackman said their average cost on Valeant Pharma (VRX) is $186
October 30, 2015 11:11 AM EDTOn Valeant Pharma (NYSE: VRX) call, Bill Ackman said their average cost is $186
... More